NanoViricides FY26 net loss narrows 13% to $8.22 million; revenue remains no revenue

• NanoViricides posted a net loss of $8.22 million for the year ended June 30, 2026, narrowing 13%.
• Basic and diluted loss per share improved to $0.41, compared with $0.63 a year earlier.
• Research and development expense fell 15% to $4.71 million, while general and administrative costs dropped 11% to $3.6 million.
• It reported no revenue for the year.
• Cash and cash equivalents were $2.8 million at June 30, 2026, and management flagged substantial doubt about going-concern funding for 12 months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-111390), on September 28, 2026, and is solely responsible for the information contained therein.